Rhythm Management

Transforming lives with groundbreaking technologies that address irregular heart rhythms, heart failure and sudden cardiac arrest.
We are relentlessly committed to providing patients with the most life-enhancing and least-invasive therapies, while serving healthcare professionals with the solutions they need to enhance patients’ lives, improve outcomes and reduce costs.

Delivering Meaningful Innovation. We’re dedicated to helping patients live longer, healthier lives with the introduction of our innovative RESONATE™ Cardiac Resynchronization Therapy Defibrillator (CRT-D) systems, a family of devices featuring SmartCRT™ that equips physicians with smart solutions to optimize where, when, and how to pace, introducing a new era of personalized CRT therapy.

Subcutaneous Implantable Cardioverter Defibrillator (S-ICD). Supported by 15 years of clinical data, our S-ICD is the first and only ICD system that leaves the heart untouched and protects patients from sudden cardiac arrest (SCA), while avoiding risks and complications associated with transvenous leads.

Bringing Clarity to the EP Lab. Engineered with clinically meaningful innovations, our RHYTHMIA HDx™ Mapping System equips electrophysiologists with unprecedented visualization in every ablation procedure.

RHYTHMIA HDx received an Innovation Award at 2017 EHRA-EUROPACE CARDIOSTIM

Conditions We Help Treat

Cardiac Arrhythmias, Heart Rhythm Disorders, Sudden Cardiac Arrest, Heart Failure

Solutions We Offer

Cardiac Rhythm Management:
Rhythmia™ Mapping System - World’s most advanced 3-D mapping system Advanced, flexible architecture High-resolution validation maps

Patient Impact



* Ellis C, Markus T, Dickerman D, Orton J, Hassan S, Good E, Okabe T, Greenspon A. Ampere Hour as a Predictor of CRT ICD Pulse Generator Longevity: A Multi-Center Study. Presented at HFSA 2014.http://www.onlinejcf.com/article/S1071-9164(14)00337-6/fulltext. Ampere Hour (Ah) as a Predictor of CRT ICD Pulse Generator Battery Longevity Study. The five major institutions performing the study include, at Vanderbilt University, Eastside Cardiovascular Medicine, University of Michigan, Thomas Jefferson University, Robert Wood Johnson University Hospital, Cooper Health System and North Ohio Research. Boston Scientific = 266 patients, Medtronic = 542 patients, St. Jude Medical = 149 patients. Five-year survival rate calculated using device replacements for battery depletion as indicated by ERI.

** Modeling shows EnduraLife Technology saved the US healthcare system approximately $300 million in 2015. Avoided explants were modeled by comparing Boston Scientific's actual explant volumes in 2015 with those predicted by a model seeded with pre-EnduraLife longevities. Devices made by other manufacturers were not included in the model. Savings were quantified using an average reimbursement value for outpatient ICD replacement.